Stockscreener 앱 받기
4.70
7.13%
-0.35
전일 마감가:
$5.05
열려 있는:
$4.87
하루 거래량:
303.17K
Relative Volume:
0.69
시가총액:
$102.61M
수익:
$66.59M
순이익/손실:
$-104.93M
주가수익비율:
-0.9495
EPS:
-4.95
순현금흐름:
$-96.48M
1주 성능:
-17.86%
1개월 성능:
-35.22%
6개월 성능:
-58.90%
1년 성능:
-71.01%
1일 변동 폭
$4.5201
$5.01
1주일 범위
$4.5201
$5.6691
52주 변동 폭
$4.5201
$17.23
Enanta Pharmaceuticals Inc Stock (ENTA) Company Profile
명칭
Enanta Pharmaceuticals Inc
전화
617 607 0800
주소
4 KINGSBURY AVENUE, WATERTOWN, MA
ENTA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ENTA
Enanta Pharmaceuticals Inc
|
4.70 | 102.61M | 66.59M | -104.93M | -96.48M | -4.95 |
|
VRTX
Vertex Pharmaceuticals Inc
|
479.27 | 125.40B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
581.69 | 65.79B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
556.00 | 35.18B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
240.00 | 32.67B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
240.24 | 26.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Enanta Pharmaceuticals Inc Stock (ENTA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-08-09 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2023-08-08 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-12-09 | 개시 | H.C. Wainwright | Buy |
| 2022-07-06 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2022-06-01 | 업그레이드 | Evercore ISI | Underperform → In-line |
| 2021-10-07 | 개시 | Jefferies | Buy |
| 2021-09-09 | 개시 | SVB Leerink | Mkt Perform |
| 2021-01-29 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2020-11-24 | 개시 | Evercore ISI | Underperform |
| 2020-08-28 | 재개 | ROTH Capital | Buy |
| 2020-08-26 | 개시 | Piper Sandler | Overweight |
| 2020-07-27 | 업그레이드 | JMP Securities | Mkt Perform → Mkt Outperform |
| 2020-03-17 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2019-11-22 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2019-09-26 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2019-05-24 | 개시 | Wolfe Research | Outperform |
| 2019-04-23 | 업그레이드 | Berenberg | Hold → Buy |
| 2018-12-13 | 개시 | Berenberg | Hold |
| 2018-06-06 | 개시 | ROTH Capital | Buy |
| 2018-02-08 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2018-01-02 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2017-11-21 | 재확인 | RBC Capital Mkts | Outperform |
| 2017-09-15 | 개시 | RBC Capital Mkts | Outperform |
| 2017-07-11 | 업그레이드 | JMP Securities | Mkt Perform → Mkt Outperform |
| 2016-04-28 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2016-02-09 | 재확인 | Barclays | Underweight |
| 2015-10-23 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2015-10-23 | 업그레이드 | JMP Securities | Mkt Perform → Mkt Outperform |
모두보기
Enanta Pharmaceuticals Inc 주식(ENTA)의 최신 뉴스
Enanta stock hits 52-week low at $4.71 amid market challenges By Investing.com - Investing.com South Africa
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Not Doing Enough For Some Investors As Its Shares Slump 27% - simplywall.st
Enanta Pharmaceuticals at H.C. Wainwright: Strategic Shift to Immunology By Investing.com - Investing.com Canada
(ENTA) Proactive Strategies - news.stocktradersdaily.com
Drug Co. Wants Fed. Circ. To Undo Pfizer COVID Patent Win - Law360
Enanta Reveals Latest Autoimmune Drug Progress: Key Presentation March 27 - StockTitan
How To Trade (ENTA) - Stock Traders Daily
Enanta Pharmaceuticals to Present at the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference - Yahoo Finance
Enanta Pharmaceuticals Reports Q1 EPS Loss of $1.05, Beating Est - GuruFocus.com
Enanta Pharmaceuticals to Present Data for its Respiratory Syncytial Virus Program at the 13 - Business Wire
Breakthrough RSV Treatment Data: Enanta Reveals Phase 2 Results for Dual Drug Programs - Stock Titan
Insider Buying: Jay Luly Acquires 45,000 Shares of Enanta Pharma - GuruFocus.com
Investor Network: Enanta Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire
Enanta Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire
Enanta Pharmaceuticals (NASDAQ:ENTA) Stock Crosses Below 200 Day Moving AverageHere's What Happened - MarketBeat
(ENTA) Trading Advice - Stock Traders Daily
Market Watch Highlights: Enanta Pharmaceuticals Inc (ENTA) Ends on an Upturn Note at 8.30 - The Dwinnex
Enanta Pharmaceuticals (NASDAQ:ENTA) Upgraded at StockNews.com - MarketBeat
Enanta Pharmaceuticals (NASDAQ:ENTA) Upgraded to “Hold” at StockNews.com - Defense World
HC Wainwright Has Pessimistic Outlook of ENTA Q2 Earnings - MarketBeat
Enanta Pharmaceuticals' SWOT analysis: RSV and immunology drive stock outlook - MSN
Analysts Set Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Price Target at $17.25 - MarketBeat
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) CEO Purchases $256,050.00 in Stock - MarketBeat
Enanta Pharmaceuticals CEO Luly Jay R. buys $256,050 in common stock - MSN
Enanta Pharmaceuticals (NASDAQ:ENTA) Cut to "Sell" at StockNews.com - MarketBeat
JMP Securities maintains Enanta stock with $21 target - MSN
With Enanta Pharmaceuticals Up 46%, Insider Buyers Count Their Returns - Yahoo Finance
President of Enanta Pharmaceuticals Picks Up 5.9% More Stock - Yahoo Finance
Enanta Pharmaceuticals (ENTA) Moves to Buy: Rationale Behind the Upgrade - MSN
Enanta Pharmaceuticals (NASDAQ:ENTA) Receives "Market Outperform" Rating from JMP Securities - MarketBeat
Enanta Pharmaceuticals, Inc.'s (NASDAQ:ENTA) Shares Bounce 55% But Its Business Still Trails The Industry - Simply Wall St
Enanta Pharmaceuticals’ (ENTA) “Buy” Rating Reiterated at HC Wainwright - Defense World
HC Wainwright maintains $18 target on Enanta shares, affirms Buy - MSN
Enanta Pharmaceuticals (NASDAQ:ENTA) Releases Quarterly Earnings Results - MarketBeat
Enanta Pharmaceuticals Advances in Virology and Immunology - TipRanks
Enanta Pharmaceuticals CEO Luly Jay R. buys $256,050 in common stock By Investing.com - Investing.com South Africa
ENANTA Pharmaceuticals CEO Acquires 45,000 Shares - TradingView
Enanta Pharmaceuticals Inc. (ENTA) reports earnings - Quartz
ENANTA PHARMACEUTICALS INC SEC 10-Q Report - TradingView
Enanta Pharmaceuticals (ENTA) Reports Q1 Loss, Tops Revenue Estimates - MSN
Enanta Pharmaceuticals (NASDAQ:ENTA) Downgraded by StockNews.com to “Sell” - Defense World
JMP Securities maintains Enanta stock with $21 target By Investing.com - Investing.com Australia
Enanta Pharmaceuticals Inc (ENTA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.65%
0.06%
자본화:
|
볼륨(24시간):